BIOLARGO, INC. (BLGO) Form 10-Q — Aug 14, 2026
BioLargo's Q2 2026 revenue fell 55% year over year to $1.25 million while its quarterly net loss more than doubled to $4.0 million from $1.9 million, driven largely by the collapse of the Pooph private-label product channel after the customer defaulted on payments. The company disclosed substantial doubt about its ability to continue as a going concern: cash fell to $2.19 million from $3.88 million at year-end, the company ran a $1.27 million working capital deficit, and total stockholders' equity flipped to a $2.73 million deficit as of June 30, 2026. BioLargo is suing former pet-odor partner Pooph Inc.
Key figures
- Revenue
- 2363000
- Total Debt
- approximately 5106000 (carrying value, incl. Clyra Medical notes net of discount)
- Revenue Yoy
- -60.9% (six months ended June 30, 2026 vs. prior year)
- Total Assets
- 6669000
- Cash Position
- 2188000
- Interest Rate
- 15% per annum (Clyra Medical guaranteed promissory notes)
- Shares Outstanding
- 328731362
- Q2 revenue
- 1248000
- Q2 net loss
- -4000000
- Q2 revenue yoy
- -55.1%
- Working capital deficit
- 1266000
- Pooph disputed royalties
- 1378141
- Clearthink equity commitment
- 10000000
- Clyra secured notes outstanding
- 1500000
- Pooph disputed product invoices
- 2385468
- Closing stock price june 30 2026
- 0.11
- Clyra guaranteed notes outstanding
- 3970000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.